Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
NASDAQ:LGND
| Market Cap (Intraday) | 1.20B |
| Current PE | N/A |
| Forward PE | 23.59 |
| 2yr Forward PE | 26.13 |
| 10-Day MA | $71.05 |
| 50-Day MA | $69.38 |
| 200-Day MA | $67.69 |
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B Stock, NASDAQ:LGND
5980 Horton Street, Suite 405, Emeryville, California 94608
United States of America
Phone: +1.858.550.7500
Number of Employees: 154
Description
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Emeryville, CA.